JP2017506505A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017506505A5 JP2017506505A5 JP2016549076A JP2016549076A JP2017506505A5 JP 2017506505 A5 JP2017506505 A5 JP 2017506505A5 JP 2016549076 A JP2016549076 A JP 2016549076A JP 2016549076 A JP2016549076 A JP 2016549076A JP 2017506505 A5 JP2017506505 A5 JP 2017506505A5
- Authority
- JP
- Japan
- Prior art keywords
- binding agent
- seq
- agent according
- cdr3
- cdr1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000011230 binding agent Substances 0.000 claims description 66
- 102000003840 Opioid Receptors Human genes 0.000 claims description 24
- 108090000137 Opioid Receptors Proteins 0.000 claims description 24
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 13
- 102000005962 receptors Human genes 0.000 claims description 13
- 108020003175 receptors Proteins 0.000 claims description 13
- 108060003951 Immunoglobulin Proteins 0.000 claims description 12
- 150000001875 compounds Chemical class 0.000 claims description 12
- 102000018358 immunoglobulin Human genes 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 7
- 239000003446 ligand Substances 0.000 claims description 6
- 150000007523 nucleic acids Chemical class 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 5
- 108091006027 G proteins Proteins 0.000 claims description 4
- 102000030782 GTP binding Human genes 0.000 claims description 4
- 108091000058 GTP-Binding Proteins 0.000 claims description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 4
- 102000051367 mu Opioid Receptors Human genes 0.000 claims description 4
- 108020001612 μ-opioid receptors Proteins 0.000 claims description 4
- 102000016979 Other receptors Human genes 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 238000002425 crystallisation Methods 0.000 claims description 2
- 230000008025 crystallization Effects 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 238000007876 drug discovery Methods 0.000 claims description 2
- 239000012634 fragment Substances 0.000 claims description 2
- 230000003834 intracellular effect Effects 0.000 claims description 2
- 239000012528 membrane Substances 0.000 claims description 2
- 108020004707 nucleic acids Proteins 0.000 claims description 2
- 102000039446 nucleic acids Human genes 0.000 claims description 2
- 229920001184 polypeptide Polymers 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 2
- 238000012216 screening Methods 0.000 claims description 2
- 230000007781 signaling event Effects 0.000 claims description 2
- 150000003384 small molecules Chemical class 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 208000024891 symptom Diseases 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims 3
- 101710122576 Isocitrate lyase 2 Proteins 0.000 claims 1
- 230000000707 stereoselective effect Effects 0.000 claims 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000004634 pharmacological analysis method Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461933742P | 2014-01-30 | 2014-01-30 | |
| US61/933,742 | 2014-01-30 | ||
| PCT/EP2015/051991 WO2015121092A1 (en) | 2014-01-30 | 2015-01-30 | Opioid receptor binding agents and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017506505A JP2017506505A (ja) | 2017-03-09 |
| JP2017506505A5 true JP2017506505A5 (enExample) | 2018-03-08 |
| JP6687525B2 JP6687525B2 (ja) | 2020-04-22 |
Family
ID=52434839
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016549076A Active JP6687525B2 (ja) | 2014-01-30 | 2015-01-30 | オピオイド受容体結合剤およびその使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US10233241B2 (enExample) |
| EP (1) | EP3099707B1 (enExample) |
| JP (1) | JP6687525B2 (enExample) |
| AU (1) | AU2015217846B2 (enExample) |
| CA (1) | CA2936728C (enExample) |
| WO (1) | WO2015121092A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201014715D0 (en) | 2010-09-06 | 2010-10-20 | Vib Vzw | Nanobodies stabilizing functional conformational states of GPCRS |
| CA2936728C (en) | 2014-01-30 | 2023-06-20 | Vib Vzw | Opioid receptor binding agents and uses thereof |
| GB201601690D0 (en) | 2016-01-29 | 2016-03-16 | Heptares Therapeutics Ltd | G proteins |
| US11668021B2 (en) | 2017-05-09 | 2023-06-06 | Yale University | Basehit, a high-throughput assay to identify proteins involved in host-microbe interaction |
| CN111526887B (zh) | 2017-10-11 | 2023-12-01 | 南京传奇生物科技有限公司 | 用于使血清中的蛋白质半衰期增加的组合物和方法 |
| EP3963328A1 (en) * | 2019-04-29 | 2022-03-09 | Confo Therapeutics N.V. | Chimeric proteins and methods to screen for compounds and ligands binding to gpcrs |
| WO2021140205A1 (en) | 2020-01-10 | 2021-07-15 | Confo Therapeutics N.V. | Methods for generating antibodies and antibody fragments and libraries comprising same |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1589107E (pt) | 1992-08-21 | 2010-03-29 | Univ Bruxelles | Imunoglobulinas desprovidas de cadeias leves |
| DK0698097T3 (da) | 1993-04-29 | 2001-10-08 | Unilever Nv | Produktion af antistoffer eller (funktionaliserede) fragmenter deraf afledt af Camelidae-immunoglobuliner med tung kæde |
| US5882944A (en) * | 1993-06-23 | 1999-03-16 | The Regents Of The University Of California | Methods for G protein coupled receptor activity screening |
| FR2708622B1 (fr) | 1993-08-02 | 1997-04-18 | Raymond Hamers | Vecteur recombinant contenant une séquence d'un gène de lipoprotéine de structure pour l'expression de séquences de nucléotides. |
| EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
| AU740043B2 (en) | 1996-06-27 | 2001-10-25 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Recognition molecules interacting specifically with the active site or cleft of a target molecule |
| AU3596599A (en) | 1998-01-26 | 1999-08-09 | Unilever Plc | Method for producing antibody fragments |
| WO2000040968A1 (en) | 1999-01-05 | 2000-07-13 | Unilever Plc | Binding of antibody fragments to solid supports |
| ATE276359T1 (de) | 1999-01-19 | 2004-10-15 | Unilever Nv | Verfahren zur herstellung von antikörperfragmenten |
| CN100434441C (zh) | 1999-04-22 | 2008-11-19 | 荷兰联合利华有限公司 | 利用单价抗原-结合蛋白抑制病毒感染 |
| US6479280B1 (en) | 1999-09-24 | 2002-11-12 | Vlaams Interuniversitair Institutuut Voor Biotechnologie Vzw | Recombinant phages capable of entering host cells via specific interaction with an artificial receptor |
| AU1859201A (en) | 1999-11-29 | 2001-06-12 | Unilever Plc | Immobilisation of proteins |
| PT1233987E (pt) | 1999-11-29 | 2009-12-28 | Bac Ip B V | Imobilização de moléculas de ligação ao antigénio de um domínio |
| ES2324280T3 (es) | 2000-03-14 | 2009-08-04 | Unilever N.V. | Dominios variables de la cadena pesada de anticuerpos frente a lipasas dieteticas humanas y sus usos. |
| CA2380443C (en) | 2000-05-26 | 2013-03-12 | Ginette Dubuc | Single-domain antigen-binding antibody fragments derived from llama antibodies |
| WO2002048193A2 (en) | 2000-12-13 | 2002-06-20 | Unilever N.V. | Camelidae antibody arrays |
| GB0110029D0 (en) | 2001-04-24 | 2001-06-13 | Grosveld Frank | Transgenic animal |
| US7371849B2 (en) | 2001-09-13 | 2008-05-13 | Institute For Antibodies Co., Ltd. | Methods of constructing camel antibody libraries |
| JP2005289809A (ja) | 2001-10-24 | 2005-10-20 | Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) | 突然変異重鎖抗体 |
| AU2002360068B2 (en) | 2001-12-21 | 2009-09-03 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Method for cloning of variable domain sequences |
| CA2471645A1 (en) | 2002-01-03 | 2003-07-10 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Immunoconjugates useful for treatment of tumours |
| GB0228210D0 (en) | 2002-12-03 | 2003-01-08 | Babraham Inst | Single chain antibodies |
| MXPA05007151A (es) | 2002-12-31 | 2005-09-21 | Nektar Therapeutics Al Corp | Polimeros terminados en maleimida hidroliticamente estables. |
| CA2595682A1 (en) | 2005-01-31 | 2006-08-03 | Ablynx N.V. | Method for generating variable domain sequences of heavy chain antibodies |
| DK1888641T3 (da) | 2005-05-18 | 2012-04-23 | Ablynx Nv | Serumalbuminbindende proteiner |
| BRPI0609797B8 (pt) | 2005-05-20 | 2021-05-25 | Ablynx Nv | nanocorpos melhorados para o tratamento de desordens mediadas por agregação |
| US8629244B2 (en) | 2006-08-18 | 2014-01-14 | Ablynx N.V. | Interleukin-6 receptor binding polypeptides |
| EP2121757A2 (en) | 2007-02-21 | 2009-11-25 | Ablynx N.V. | Amino acid sequences directed against vascular endothelial growth factor and polypeptides comprising the same for the treatment of conditions and diseases characterized by excessive and/or pathological angiogenesis or neovascularization |
| CA2687903C (en) | 2007-05-24 | 2016-09-13 | Ablynx N.V. | Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders |
| FR2916977A1 (fr) * | 2007-06-06 | 2008-12-12 | Engelhard Lyon Sa | STIMULATION DE LA SYNTHESE DES RECPTEURS MCR1, MCR2 ET µ OPIOIDE. |
| AU2009326075B2 (en) | 2008-12-08 | 2014-06-05 | Complix Nv | Single-chain antiparallel coiled coil proteins |
| CN102257003B (zh) | 2008-12-19 | 2017-04-05 | 埃博灵克斯股份有限公司 | 用于产生针对细胞相关抗原如p2x7、cxcr7或cxcr4的免疫球蛋白的基因免疫 |
| WO2011083141A2 (en) | 2010-01-08 | 2011-07-14 | Ablynx Nv | Method for generation of immunoglobulin sequences by using lipoprotein particles |
| DK2611826T3 (en) | 2010-08-30 | 2017-01-09 | Confometrx Inc | A method and composition for the crystallization of a family-C-GPCR |
| US8765414B2 (en) | 2011-03-15 | 2014-07-01 | The Board Of Trustees Of The Leland Stanford Junior University | GPCR fusion protein containing an N-terminal autonomously folding stable domain, and crystals of the same |
| JP2014516963A (ja) | 2011-05-13 | 2014-07-17 | レセプトス インコーポレイテッド | Ｇタンパク質共役レセプターを結晶化するための新規融合パートナー |
| CA2899693C (en) * | 2013-01-30 | 2023-03-14 | Vib Vzw | Novel chimeric polypeptides for screening and drug discovery purposes |
| CA2936728C (en) | 2014-01-30 | 2023-06-20 | Vib Vzw | Opioid receptor binding agents and uses thereof |
-
2015
- 2015-01-30 CA CA2936728A patent/CA2936728C/en active Active
- 2015-01-30 US US15/115,621 patent/US10233241B2/en active Active
- 2015-01-30 JP JP2016549076A patent/JP6687525B2/ja active Active
- 2015-01-30 AU AU2015217846A patent/AU2015217846B2/en active Active
- 2015-01-30 EP EP15701821.9A patent/EP3099707B1/en active Active
- 2015-01-30 WO PCT/EP2015/051991 patent/WO2015121092A1/en not_active Ceased
-
2019
- 2019-03-15 US US16/355,442 patent/US11352422B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017506505A5 (enExample) | ||
| RU2481355C2 (ru) | Аминокислотные последовательности, направленные на rank-l, и полипептиды, включающие их, для лечения заболеваний и нарушений костей | |
| Naved et al. | Kidney repair and regeneration: perspectives of the NIDDK (Re) Building a Kidney consortium | |
| Alexander et al. | Target highlights in CASP14: Analysis of models by structure providers | |
| US11814426B2 (en) | Anti-tenascin C antibodies and uses thereof | |
| US20100256341A1 (en) | Treatment of inflammation using alpha 7 receptor-binding cholinergic agonists | |
| RU2013153592A (ru) | Анти-mif антитела | |
| JP2013541335A5 (enExample) | ||
| HRP20170254T1 (hr) | Humanizirana i kimerna monoklonska protutijela usmjerena na cd47 | |
| WO2008031133A3 (en) | Borrelia antigens | |
| Li et al. | Preparation of a chicken scFv to analyze gentamicin residue in animal derived food products | |
| JP6587609B2 (ja) | 強皮症治療のための抗ｃｃｌ２及び抗ｌｏｘｌ２併用療法 | |
| WO2022061594A1 (zh) | 新型冠状病毒（sars-cov-2）刺突蛋白结合分子及其应用 | |
| RU2014132108A (ru) | Slit-robo сигналинг для диагностики и лечения заболевания почек | |
| RU2013123270A (ru) | Структуры слитого белка шелка пауков для связывания с органической мишенью | |
| CN108350050A (zh) | 淀粉样蛋白β中的表位及其构象选择性抗体 | |
| Wu et al. | Structure and analysis of nanobody binding to the human ASIC1a ion channel | |
| WO2006116442A3 (en) | Monoclonal antibodies and methods for their use in the detection of cervical disease | |
| JP6884785B2 (ja) | 抗ｃｄ９５ｌ抗体 | |
| JP2014509860A5 (enExample) | ||
| Wei et al. | Ultrasensitive “Hunter of Target”: Rabbit Monoclonal Antibody-Based Competitive Lateral Flow Immunoassay for Saxitoxin | |
| EP3992205A1 (en) | Sars coronavirus-2 spike protein binding compounds | |
| Al-Ramahi et al. | ssDNA recombineering boosts in vivo evolution of nanobodies displayed on bacterial surfaces | |
| CN108251429A (zh) | 一种与甲胺磷特异性结合的核酸适配体Met-G02及其应用 | |
| JP2014506448A5 (enExample) |